NetraMark Holdings (AIAI:TSX). It was only a matter of time before some bright spark married AI with pharmaceutical endeavours. NetraMark is a company focused on being a leader in developing Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that can simultaneously parse patient data sets into subsets of strongly related people according to several variables. (Corp Website)
The global AI in drug discovery market size was USD 1.99 billion in 2024, estimated at USD 2.65 billion in 2025, and is expected to reach around USD 35.42 billion by 2034, expanding at a CAGR of 29.6% from 2025 to 2034.
This approach’s proven efficacy, efficiencies, and costs open the door to more life-saving companies that are on the cutting edge, revolutionizing the development and speed of the pharmaceutical sector. Charts may exaggerate, but they don’t lie. The action looks measured and, frankly, enticing. StockResearchtoday.com identified five stellar reasons for several types of investors to consider.
Through advanced modelling, NetraMark’s platform analyzes preclinical data to predict how new drug candidates may perform in human trials, significantly improving the decision-making process before clinical testing begins.
1. AI-Driven Drug Development | NetraMark’s proprietary AI models offer deep insights into patient data, providing pharmaceutical companies with a competitive edge in drug discovery and trial optimization. NetraMark redefines how treatment strategies are developed and executed by integrating cutting-edge ML algorithms.
2. Strategic Industry Partnerships | The Company recently announced a pilot collaboration with a top-five pharmaceutical company, demonstrating strong industry confidence in its technology. These partnerships open new doors for future licensing agreements, revenue streams, and increased adoption across biotech and pharma.
3. Unmatched Clinical Trial Optimization | NetraMark’s AI platform can reduce failure rates by analyzing trial data in real-time, identifying key subpopulations, and adjusting protocols for better patient matching. This significantly improves the probability of clinical success, a game-changer in a sector where trial failures can cost companies billions.
4. A Leadership Team with Deep Expertise | The Company is guided by AI specialists, pharmaceutical executives, and clinical research pioneers, including Dr. Joseph Geraci, a renowned figure in AI-driven medicine. This combination of technical and industry knowledge ensures a clear strategy for scaling and adoption.
5. Strengthening Financial Position for Expansion | With a recent capital infusion of $1.16 million from warrant and stock option exercises, NetraMark is well-positioned to scale operations, invest in further AI advancements, and expand its market reach.
NIH: Using reinforcement learning and generative models, AI algorithms can propose novel drug-like chemical structures. By learning from chemical libraries and experimental data, AI expands the chemical space and aids in developing innovative drug candidates.
The above statement encapsulates NetraMark and the sector’s raison d’etre for most humans. (I couldn’t find the hat that goes over the first-Excusez moi)
Who else is in this market: Arguably not as developmental as NetraMark;
1. Sanofi with Aily Labs
2. Pfizer and IBM
3. Novartis
4. Janssen
5. AstraZeneca with Oncoshot
6. Bristol Myers Squibb with Exscientia
7. Bayer with Exscientia
8. Merck with BenchSci
9. GSK Cloud Pharmaceutical et al.
10. Roche with Recursion Pharmaceutical.
Lilly, the final big Pharma company in the sector, explains AI in Pharma reasonably.
Lilly, a $420 billion Big Pharma, recently told Insider it aims to grow its ‘digital worker-equivalent workforce’ to 2.4 million hours, or 274 years of human work, by year-end through more than 100 AI projects. CEO David Ricks noted that he sees AI augmenting human productivity, automating regulatory processes, and enabling new drug discovery constructs chemists wouldn’t visualize alone. Ricks expects AI to ‘massively change the productivity of the workplace,’ freeing people for more valuable work.
I will admit that when I first got the assignment, there was a significant amount of eye-rolling and head-banging on the desk. That changed once I dug in. When some cash comes my way, I’ll get some.
Why? It’s not that important that investors understand the minutia but how the tech makes us safer and healthier and likely causes us to live longer.
Bob Beaty
For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.
Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)
Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;
‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.
Let’s go.
